EMA — authorised 29 April 2022
- Marketing authorisation holder: IDORSIA PHARMACEUTICALS DEUTSCHLAND GMBH
- Status: approved
🇪🇺 Quviviq in European Union
EMA authorised Quviviq on 29 April 2022
Marketing authorisation
Quviviq in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Neuroscience approved in European Union
Frequently asked questions
Is Quviviq approved in European Union?
Yes. EMA authorised it on 29 April 2022.
Who is the marketing authorisation holder for Quviviq in European Union?
IDORSIA PHARMACEUTICALS DEUTSCHLAND GMBH holds the EU marketing authorisation.